Is Addex Therapeutics Ltd. (ADXN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 37.9% / 30% | 0.2% / 30% | 2.27% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 37.9% / 33% | 0.2% / 33% | 2.27% / 5% | ✗ NOT HALAL |
| MSCI | 0.4% / 33% | 31.4% / 33% | 0.1% / 33% | 2.27% / 5% | ✓ HALAL |
| S&P | 0.5% / 33% | 37.9% / 33% | 0.2% / 33% | 2.27% / 5% | ✗ NOT HALAL |
| FTSE | 0.4% / 33% | 31.4% / 33% | 0.1% / 50% | 2.27% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1403.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -72.8% | |
| Return on Assets (ROA) | -15.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Total Debt | $41,994 |
| Debt-to-Equity | 0.6 |
| Current Ratio | 2.0 |
| Total Assets | $11M |
Price & Trading
| Last Close | $6.30 |
| 50-Day MA | $7.32 |
| 200-Day MA | $8.24 |
| Avg Volume | 5K |
| Beta | 1.9 |
|
52-Week Range
$5.57
| |
About Addex Therapeutics Ltd. (ADXN)
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Addex Therapeutics Ltd. (ADXN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Addex Therapeutics Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Addex Therapeutics Ltd.'s debt ratio?
Addex Therapeutics Ltd.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Addex Therapeutics Ltd.'s key financial metrics?
Addex Therapeutics Ltd. has a market capitalization of $8M, and revenue of $404,102. Return on equity stands at -72.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.